BIOFILCHEM

Biofil Chemicals & Pharmaceuticals Share Price

₹59.64 +0.13 (0.22%)

28 Dec, 2024 00:38

SIP TrendupStart SIP in BIOFILCHEM

Start SIP

Performance

  • Low
  • ₹60
  • High
  • ₹60
  • 52 Week Low
  • ₹53
  • 52 Week High
  • ₹92
  • Open Price₹60
  • Previous Close₹60
  • Volume13,774

Investment Returns

  • Over 1 Month -4.04%
  • Over 3 Month -23.02%
  • Over 6 Month -8.5%
  • Over 1 Year + 5%
SIP Lightning

Smart Investing Starts Here Start SIP with Biofil Chemicals & Pharmaceuticals for Steady Growth!

Invest Now

Biofil Chemicals & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 181.2
  • PEG Ratio
  • -8.7
  • Market Cap Cr
  • 97
  • P/B Ratio
  • 5.3
  • Average True Range
  • 2.9
  • EPS
  • 0.33
  • Dividend Yield
  • 0
  • MACD Signal
  • -1
  • RSI
  • 38.25
  • MFI
  • 22.97

Biofil Chemicals & Pharmaceuticals Financials

Biofil Chemicals & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹59.64
+ 0.13 (0.22%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹62.30
  • 50 Day
  • ₹64.55
  • 100 Day
  • ₹65.91
  • 200 Day
  • ₹64.99

Resistance and Support

59.87 Pivot Speed
  • R3 61.23
  • R2 60.85
  • R1 60.25
  • S1 59.27
  • S2 58.89
  • S3 58.29

What's your outlook on Biofil Chemicals & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Biofil Chemicals & Pharmaceuticals has an operating revenue of Rs. 31.09 Cr. on a trailing 12-month basis. An annual revenue growth of 35% is outstanding, Pre-tax margin of 2% needs improvement, ROE of 3% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 16 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Biofil Chemicals & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-02-06 Quarterly Results
2023-11-09 Quarterly Results

Biofil Chemicals & Pharmaceuticals F&O

Biofil Chemicals & Pharmaceuticals Shareholding Pattern

46.82%
0%
0.04%
38.02%
15.12%

About Biofil Chemicals & Pharmaceuticals

  • NSE Symbol
  • BIOFILCHEM
  • BSE Symbol
  • 524396
  • Chairman & Managing Director
  • Mr. Ramesh Shah
  • ISIN
  • INE829A01014

Similar Stocks to Biofil Chemicals & Pharmaceuticals

Biofil Chemicals & Pharmaceuticals FAQs

Biofil Chemicals & Pharmaceuticals share price is ₹59 As on 28 December, 2024 | 00:24

The Market Cap of Biofil Chemicals & Pharmaceuticals is ₹97.1 Cr As on 28 December, 2024 | 00:24

The P/E ratio of Biofil Chemicals & Pharmaceuticals is 181.2 As on 28 December, 2024 | 00:24

The PB ratio of Biofil Chemicals & Pharmaceuticals is 5.3 As on 28 December, 2024 | 00:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23